6iea - Revision history

OCA at 06:24, 10 July 2019

2019-07-10T06:24:39Z

←Older revision		Revision as of 06:24, 10 July 2019
Line 3:		Line 3:
	<StructureSection load='6iea' size='340' side='right'caption='[[6iea]], [[Resolution\|resolution]] 2.00Å' scene=''>		<StructureSection load='6iea' size='340' side='right'caption='[[6iea]], [[Resolution\|resolution]] 2.00Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6iea]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6IEA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6IEA FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6iea]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Rvfv Rvfv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6IEA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6IEA FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6iea FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6iea OCA], [http://pdbe.org/6iea PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6iea RCSB], [http://www.ebi.ac.uk/pdbsum/6iea PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6iea ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6iea FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6iea OCA], [http://pdbe.org/6iea PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6iea RCSB], [http://www.ebi.ac.uk/pdbsum/6iea PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6iea ProSAT]</span></td></tr>
Line 20:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
		+	[[Category: Rvfv]]
	[[Category: Gao, F]]		[[Category: Gao, F]]
	[[Category: Gao, G F]]		[[Category: Gao, G F]]
Line 27:		Line 29:
	[[Category: Wu, Y]]		[[Category: Wu, Y]]
	[[Category: Antibody]]		[[Category: Antibody]]
-	[[Category: Rvfv]]
	[[Category: Structural protein]]		[[Category: Structural protein]]
	[[Category: Structural protein-immune system complex]]		[[Category: Structural protein-immune system complex]]

OCA at 07:22, 10 April 2019

2019-04-10T07:22:21Z

←Older revision		Revision as of 07:22, 10 April 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6iea is ~~ON HOLD~~	+	==Structure of RVFV Gn and human monoclonal antibody R13==
		+	<StructureSection load='6iea' size='340' side='right'caption='[[6iea]], [[Resolution\|resolution]] 2.00Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6iea]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6IEA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6IEA FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6iea FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6iea OCA], [http://pdbe.org/6iea PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6iea RCSB], [http://www.ebi.ac.uk/pdbsum/6iea PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6iea ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific monoclonal antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific monoclonal antibodies. The Gn monoclonal antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific monoclonal antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.

-	~~Authors: Wang~~, Q~~.H.~~, Wu, Y., ~~Gao~~, F., Qi, J~~.X.~~, Gao, G.F.	+	Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus.,Wang Q, Ma T, Wu Y, Chen Z, Zeng H, Tong Z, Gao F, Qi J, Zhao Z, Chai Y, Yang H, Wong G, Bi Y, Wu L, Shi R, Yang M, Song J, Jiang H, An Z, Wang J, Yilma TD, Shi Y, Liu WJ, Liang M, Qin C, Gao GF, Yan J Nat Microbiol. 2019 Apr 1. pii: 10.1038/s41564-019-0411-z. doi:, 10.1038/s41564-019-0411-z. PMID:30936489<ref>PMID:30936489</ref>

-	~~Description: Structure~~ of ~~RVFV Gn and human monoclonal antibody R13~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[Category: Unreleased Structures]]~~	+	</div>
-	~~[[Category~~: ~~Qi, J.X]]~~	+	<div class="pdbe-citations 6iea" style="background-color:#fffaf0;"></div>
-	[[Category: ~~Gao, G.F~~]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Gao, F]]		[[Category: Gao, F]]
-	[[Category: Wang, Q.H]]	+	[[Category: Gao, G F]]
		+	[[Category: Qi, J X]]
		+	[[Category: Wang, Q H]]
	[[Category: Wu, Y]]		[[Category: Wu, Y]]
		+	[[Category: Antibody]]
		+	[[Category: Rvfv]]
		+	[[Category: Structural protein]]
		+	[[Category: Structural protein-immune system complex]]

OCA: Protected "6iea" [edit=sysop:move=sysop]

2018-09-19T18:20:17Z

Protected "6iea" [edit=sysop:move=sysop]

←Older revision

Revision as of 18:20, 19 September 2018

OCA: New page: '''Unreleased structure''' The entry 6iea is ON HOLD Authors: Wang, Q.H., Wu, Y., Gao, F., Qi, J.X., Gao, G.F. Description: Structure of RVFV Gn and human monoclonal antibody R13 [[Cat...

2018-09-19T18:20:15Z

New page: '''Unreleased structure''' The entry 6iea is ON HOLD Authors: Wang, Q.H., Wu, Y., Gao, F., Qi, J.X., Gao, G.F. Description: Structure of RVFV Gn and human monoclonal antibody R13 [[Cat...

New page

'''Unreleased structure'''

The entry 6iea is ON HOLD

Authors: Wang, Q.H., Wu, Y., Gao, F., Qi, J.X., Gao, G.F.

Description: Structure of RVFV Gn and human monoclonal antibody R13
[[Category: Unreleased Structures]]
[[Category: Qi, J.X]]
[[Category: Gao, G.F]]
[[Category: Gao, F]]
[[Category: Wang, Q.H]]
[[Category: Wu, Y]]